New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

To check if the findings apply to humans, the team also analyzed lung and windpipe tissue from smokers and non-smokers. They ...

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been ...

The 'cell of origin' of the second most common lung cancer and the way that it becomes dominant in the lung have been discovered, in a new study in mice and humans from researchers at UCL, the ...

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

A reduced dose of elective radiation is safe and does not compromise treatment efficacy in patients with head and neck ...